Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 04, 2026
DataAggregated Company Financials
Companies63
  • 7D6.5%
  • 3M-0.5%
  • 1Y11.9%
  • YTD-14.0%

Over the last 7 days, the Life Sciences industry has risen 6.5%, driven by gains from Danaher of 3.3%. This takes the industry's 12 month performance to a gain of 12%. As for the next few years, earnings are expected to grow by 17% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 05 Jun 2026US$586.5bUS$150.6bUS$13.8b37.7x42.6x3.9x
Sun, 03 May 2026US$545.1bUS$149.1bUS$13.7b36.4x39.7x3.7x
Tue, 31 Mar 2026US$533.2bUS$147.8bUS$14.1b35.4x37.9x3.6x
Thu, 26 Feb 2026US$593.7bUS$147.8bUS$14.0b34.7x42.5x4x
Sat, 24 Jan 2026US$709.3bUS$145.8bUS$12.4b36x57.4x4.9x
Mon, 22 Dec 2025US$651.7bUS$145.8bUS$12.5b34.7x52.2x4.5x
Wed, 19 Nov 2025US$640.9bUS$145.7bUS$12.2b34x52.6x4.4x
Fri, 17 Oct 2025US$617.9bUS$144.3bUS$14.6b32.8x42.5x4.3x
Sun, 14 Sep 2025US$565.3bUS$144.3bUS$14.6b28.6x38.8x3.9x
Tue, 12 Aug 2025US$550.8bUS$144.2bUS$14.4b29x38.2x3.8x
Thu, 10 Jul 2025US$543.5bUS$142.9bUS$9.1b36.5x59.5x3.8x
Sat, 07 Jun 2025US$509.9bUS$142.9bUS$9.2b35.6x55.6x3.6x
Mon, 05 May 2025US$523.7bUS$142.4bUS$9.7b37.8x54.3x3.7x
Wed, 02 Apr 2025US$572.5bUS$142.5bUS$10.0b36.7x57.4x4x
Fri, 28 Feb 2025US$616.3bUS$143.3bUS$9.7b37.7x63.3x4.3x
Sun, 26 Jan 2025US$700.4bUS$142.4bUS$10.2b45.1x68.6x4.9x
Tue, 24 Dec 2024US$652.4bUS$142.4bUS$10.2b43.7x63.8x4.6x
Thu, 21 Nov 2024US$634.5bUS$142.4bUS$10.4b42x61.3x4.5x
Sat, 19 Oct 2024US$729.7bUS$141.8bUS$8.5b37.2x85.9x5.1x
Mon, 16 Sep 2024US$740.7bUS$141.8bUS$8.5b37.5x87.2x5.2x
Wed, 14 Aug 2024US$724.4bUS$141.5bUS$8.4b39x86.7x5.1x
Fri, 12 Jul 2024US$669.1bUS$141.3bUS$12.2b40.5x54.9x4.7x
Sun, 09 Jun 2024US$713.3bUS$141.3bUS$12.2b37.7x58.6x5x
Tue, 07 May 2024US$714.1bUS$141.7bUS$12.5b39.7x57.1x5x
Thu, 04 Apr 2024US$727.8bUS$142.1bUS$12.8b43.1x56.9x5.1x
Sat, 02 Mar 2024US$735.4bUS$142.2bUS$12.8b44.2x57.4x5.2x
Mon, 29 Jan 2024US$698.4bUS$153.8bUS$14.2b35.5x49.3x4.5x
Wed, 27 Dec 2023US$698.9bUS$153.8bUS$14.2b37.8x49.1x4.5x
Fri, 24 Nov 2023US$631.0bUS$153.8bUS$14.0b33.5x45x4.1x
Sun, 22 Oct 2023US$607.7bUS$154.6bUS$11.2b31.3x54.2x3.9x
Tue, 19 Sep 2023US$688.5bUS$154.6bUS$11.2b32.7x61.4x4.5x
Thu, 17 Aug 2023US$708.0bUS$154.6bUS$11.2b32.3x63.2x4.6x
Sat, 15 Jul 2023US$706.2bUS$155.5bUS$12.7b29.3x55.7x4.5x
Mon, 12 Jun 2023US$680.2bUS$152.4bUS$12.5b29.1x54.4x4.5x
Price to Earnings Ratio

54.4x


Total Market Cap: US$680.2bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.4x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.4x which is lower than its 3-year average PE of 56.4x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.2% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.35%
Healthcare-1.17%
Life Sciences6.46%
Clinical Research and Equipment6.46%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DHR DanaherUS$186.643.3%
+US$4.3b		-2.9%PE35.9x
ILMN IlluminaUS$168.065.9%
+US$1.4b		104.3%PE29.8x
ICLR ICONUS$152.8011.7%
+US$1.2b		13.3%PE51x
IQV IQVIA HoldingsUS$186.883.2%
+US$966.4m		26.8%PE22.5x
WAT WatersUS$376.472.7%
+US$962.2m		8.7%PE82.2x

Latest News

ILMN
US$168.06
Illumina
7D
5.9%
1Y
104.3%
BRKR
US$59.97
Bruker
7D
10.3%
1Y
59.1%
STVN
US$18.51
Stevanato Group
7D
-0.8%
1Y
-20.4%
A
US$138.37
Agilent Technologies
7D
2.2%
1Y
21.4%
TXG
US$33.50
10x Genomics
7D
19.7%
1Y
267.7%
TMO
US$482.03
Thermo Fisher Scientific
7D
-1.1%
1Y
21.0%
WAT
US$376.47
Waters
7D
2.7%
1Y
8.7%
Narrative Update • Jun 03

WAT: New Omics Platforms And Buybacks Will Support Future Upside

Analysts have trimmed their price target for Waters to $460, reflecting slightly higher assumed discount rates, modestly adjusted long term revenue growth and profit margin expectations, and a lower future P/E multiple in their updated models. What's in the News Waters launched the Cyclic IMS P20 Mass Spectrometer, a structural and spatial omics platform using multipass Cyclic Ion Mobility Spectrometry and advanced fragmentation and imaging techniques, aimed at earlier detection of disease signals and more detailed molecular visualization.
ICLR
US$152.80
ICON
7D
11.7%
1Y
13.3%
Narrative Update • Jun 03

ICLR: Accounting Headwinds And 2026 Margin Pressure Will Restrain Earnings Quality

Analysts have lifted the ICON fair value estimate from $75.00 to $125.00, reflecting a reset after the accounting investigation, stronger reported bookings momentum, and updated assumptions for revenue growth, profit margins, and future P/E multiples in line with the recent wave of higher Street price targets. Analyst Commentary Street research around ICON has turned more constructive on the fair value range after the accounting investigation update, but opinions are still split on how much risk remains in the story.
DHR
US$186.64
Danaher
7D
3.3%
1Y
-2.9%
WST
US$317.32
West Pharmaceutical Services
7D
-1.4%
1Y
45.2%
OABI
US$2.66
OmniAb
7D
-2.2%
1Y
92.8%
Narrative Update • Jun 01

OABI: 2026 Revenue Guidance Will Shape Long Term Upside Potential

Analysts have nudged their price target on OmniAb slightly higher to $7.33, reflecting updated assumptions around the company’s discount rate, long term revenue growth, profit margin, and future P/E multiple. What's in the News OmniAb issued earnings guidance for 2026, projecting revenue in a range of $25 million to $30 million.
SHC
US$15.57
Sotera Health
7D
-1.1%
1Y
27.7%
IQV
US$186.88
IQVIA Holdings
7D
3.2%
1Y
26.8%
Narrative Update • May 31

IQV: Future Returns Will Depend On AI Trial Expansion And Execution Risk Balancing

Narrative Update on IQVIA Holdings The analyst price target for IQVIA Holdings has moved from $186.12 to $195.00, reflecting updated assumptions on discount rate, profit margin, and P/E, alongside recent research in which several firms reiterated constructive views on clinical trial activity, AI related cost savings, and the stock's valuation. Analyst Commentary Recent Street research on IQVIA Holdings has been mixed, with some bullish rating changes and initiations sitting alongside lower price targets from more cautious voices.
DNA
US$9.05
Ginkgo Bioworks Holdings
7D
-4.3%
1Y
25.2%
BIO
US$307.47
Bio-Rad Laboratories
7D
-3.4%
1Y
40.2%
ATLN
US$1.30
Atlantic International
7D
-6.5%
1Y
-45.1%